培美曲塞二钠联合顺铂治疗非小细胞肺癌的效果观察  

Efficacy observation of pemetrexed disodium combined with cis-platinum in the treatment of non-small cell lung cancer

作　　者：于小云[1] 

机构地区：[1]辽宁省普兰店市中心医院肿瘤内科,辽宁普兰店116200

出　　处：《中国现代医生》2016年第8期63-65,共3页China Modern Doctor

摘　　要：目的探讨培美曲塞二钠联合顺铂治疗晚期非鳞非小细胞肺癌的疗效观察。方法选择我院2012年3月～2015年3月收治的46例晚期非鳞非小细胞肺癌患者,所有患者随机分为观察组及对照组各23例。对照组采用吉西他滨联合顺铂治疗,观察组采用培美曲塞二钠联合顺铂治疗。观察两组患者的临床疗效及不良反应发生率。结果观察组患者的临床总有效率78.26%,明显高于对照组的69.57%,两组比较差异有统计学意义（P〈0.05）。观察组患者的不良反应总发生率为17.39%,明显低于对照组的34.78%,两组比较差异有统计学意义（P〈0.05）。结论对晚期非鳞非小细胞肺癌采用培美曲塞二钠联合顺铂治疗,临床疗效确切,毒性可以耐受,可提高患者的生存质量。Objective To investigate the efficacy of pemetrexed disodium combined with cis-platinum in the treatment of non-squamous and non-small cell lunhing cancer in advanced stage. Methods A total of 46 patients with non-small cell lung cancer in the advanced stage who were admitted into our hospital from March 2012 to March 2015 were selected and randomly assigned into observation group and control group with 23 cases in each group. The control group was treated with gemcitabine combined with cisplatin, the observation group was treated with pemetrexed disodium combined with cisplatin. Clinical efficacy and adverse reaction rate of the patients in both groups were observed. Results The total clinical efficacy rate of the observation group was 78.26% and was significantly higher than 69.57% of control group. The differences had statistical significance（ P〈0. 05）. The total incidence of adverse reaction of the observation group was 17.39% and was significantly lower than 34.78% of the control group, the differences were significant（P〈0.05）. Conclusion Pemetrexed disodium combined with cis-platinum in the treatment of non-squamous and non-small cell lung cancer in the advanced stage have definite clinical efficacy and the toxicity can be tolerated,which can improve the living quality of the patients.

关 键 词：培美曲塞二钠 顺铂 非鳞非小细胞肺癌 吉西他滨 

分 类 号：R734.2[医药卫生—肿瘤]